Innovation Pharmaceuticals Inc (IPIX)

[cabel]

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4123809/

Take %25 percent of this market is HUGE!

That is until we show that Brilacidin also treats UC!

UC is a gastrointestinal (GI) disease that is localized to the large intestine, or colon, where inflammation can affect either the entire organ or a portion of it.2 Approximately 1.86 billion patients have been diagnosed with UC globally, with 1.54 billion patients currently receiving treatment. Traditional therapies have yielded $4.18 billion in annual sales around the world, a figure expected to increase to $6.85 billion by 2022 with the approval of various pipeline drugs.3